PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Efficacy | ZEJULA (niraparib) for HCPs
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial - Mirza - 2023 - Cancer - Wiley Online Library
Treatment Considerations With Niraparib
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
PARP Inhibitors. - ppt download
Efficacy of Niraparib by Timing of Surgery and Residual Disease: a Post Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-301
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
